問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of Others-Lung Cancer

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

National Taiwan University Cancer Center (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

施金元SHIH, JIN-YUAN
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

241Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

施金元

List

398Cases

2020-06-01 - 2024-05-31

Phase I

Completed
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15/sIL-15Rα)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and Lymphoma

  • Condition/Disease

    Advanced Solid Tumors and Lymphoma

  • Test Drug

    NIZ985PDR001

Participate Sites
1Sites

Recruiting1Sites

2020-10-15 - 2026-12-31

Phase II

Active
Phase 2, Multicenter, Randomized Study of DS-1062a in Advanced or Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations and Previously Treated with Kinase Inhibitor Therapy and Platinum-based Chemotherapy with or without Prior Immunotherapy

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    DS-1062a

Participate Sites
4Sites

Recruiting4Sites

2024-01-15 - 2029-12-31

Phase III

Active
Beamion LUNG-2: A Phase III, open-label, randomized, active- controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non- squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

  • Condition/Disease

    unresectable, locally advanced or metastatic non- squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

  • Test Drug

    Zongertinib

Participate Sites
5Sites

Recruiting5Sites

2022-11-15 - 2034-07-12

Others

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    AlectinibEntrectinibEntrectinibPralsetinibDurvalumab

Participate Sites
8Sites

Recruiting8Sites

2022-06-01 - 2026-06-30

Phase II

A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)

  • Condition/Disease

    Extensive-stage Small-cell Lung Cancer

  • Test Drug

    Ifinatamab Deruxtecan (I-DXd)

Participate Sites
6Sites

Recruiting6Sites

2024-08-01 - 2028-03-31

Phase II

A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)

  • Condition/Disease

    Lung Cancer

  • Test Drug

    Osimertinib tablets 40 mg

Participate Sites
7Sites

Recruiting7Sites

2023-07-01 - 2030-06-30

Phase II/III

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
8Sites

Recruiting8Sites

2024-07-01 - 2027-08-31

Phase I/II

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

  • Condition/Disease

    Nonsquamous Non-small Cell Lung Cancer

  • Test Drug

    Vudalimab

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2022-05-10 - 2026-08-04

Phase III

HERTHENA–Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    Patritumab Deruxtecan (U3-1402)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2024-02-06 - 2029-08-30

Phase II

Active
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC

  • Condition/Disease

    NSCLC

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

1 24 25 26 27 28 40
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB